UroGen Historical Income Statement
| URGN Stock | USD 14.30 0.04 0.28% |
Historical analysis of UroGen Pharma income statement accounts such as Interest Expense of 38.1 M, Selling General Administrative of 94.9 M, Total Revenue of 86.8 M or Gross Profit of 77 M can show how well UroGen Pharma performed in making a profits. Evaluating UroGen Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of UroGen Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining UroGen Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether UroGen Pharma is a good buy for the upcoming year.
UroGen |
About UroGen Income Statement Analysis
UroGen Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to UroGen Pharma shareholders. The income statement also shows UroGen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
UroGen Pharma Income Statement Chart
UroGen Pharma Income Statement is one of the three primary financial statements used for reporting UroGen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of UroGen Pharma revenue and expense. UroGen Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, UroGen Pharma's Depreciation And Amortization is very stable compared to the past year. As of the 5th of May 2024, Tax Provision is likely to grow to about 1.2 M, while Operating Income is likely to drop (68.8 M). Add Fundamental
Gross Profit
Gross profit is a required income statement account that reflects total revenue of UroGen Pharma minus its cost of goods sold. It is profit before UroGen Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of UroGen Pharma. It is also known as UroGen Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from UroGen Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Depreciation And Amortization is very stable compared to the past year. As of the 5th of May 2024, Tax Provision is likely to grow to about 1.2 M, while Operating Income is likely to drop (68.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 17.3M | 1.0M | 1.7M | 3.0M | Interest Income | 365K | 938K | 2.4M | 1.9M |
UroGen Pharma income statement Correlations
Click cells to compare fundamentals
UroGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UroGen Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 4.3M | 3.7M | 17.4M | 8.4M | 36.3M | 38.1M | |
| Selling General Administrative | 60.2M | 90.2M | 39.9M | 82.8M | 90.4M | 94.9M | |
| Total Revenue | 18K | 11.8M | 48.0M | 64.4M | 82.7M | 86.8M | |
| Gross Profit | 18K | 10.8M | 42.9M | 56.7M | 73.4M | 77.0M | |
| Operating Income | (109.5M) | (126.7M) | (92.3M) | (79.0M) | (65.5M) | (68.8M) | |
| Net Income From Continuing Ops | (105.1M) | (128.5M) | (110.8M) | (109.8M) | (105.1M) | (99.8M) | |
| Ebit | (109.5M) | (126.7M) | (92.3M) | (79.0M) | (65.5M) | (68.8M) | |
| Research Development | 49.3M | 47.3M | 47.6M | 52.9M | 45.6M | 32.5M | |
| Cost Of Revenue | 48K | 1.0M | 5.2M | 7.7M | 9.4M | 9.8M | |
| Total Operating Expenses | 109.5M | 137.5M | 135.2M | 135.7M | 138.9M | 79.8M | |
| Income Before Tax | (105.1M) | (125.1M) | (109.4M) | (108.0M) | (98.3M) | (93.4M) | |
| Total Other Income Expense Net | 4.3M | 1.6M | (17.1M) | (29.0M) | (32.8M) | (31.1M) | |
| Net Income Applicable To Common Shares | (105.1M) | (128.5M) | (110.8M) | (109.8M) | (98.8M) | (93.9M) | |
| Net Income | (100.5M) | (128.5M) | (110.8M) | (109.2M) | (102.2M) | (97.1M) | |
| Income Tax Expense | (4.6M) | 3.4M | 1.4M | 1.1M | 3.9M | 4.1M | |
| Interest Income | 4.6M | 2.0M | 365K | 938K | 2.4M | 1.9M | |
| Depreciation And Amortization | 1.3M | 2.0M | 17.3M | 1.0M | 1.7M | 3.0M | |
| Other Operating Expenses | 109.5M | 138.5M | 140.3M | 143.4M | 148.2M | 99.7M | |
| Ebitda | (108.2M) | (124.7M) | (75.0M) | (78.0M) | (63.8M) | (67.0M) | |
| Net Interest Income | 4.6M | 1.6M | 212K | (7.4M) | (11.9M) | (11.3M) | |
| Tax Provision | 0.0 | 3.4M | 1.4M | 1.8M | 755K | 1.2M | |
| Reconciled Depreciation | 1.3M | 2.0M | 1.8M | 1.8M | 1.7M | 1.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.Note that the UroGen Pharma information on this page should be used as a complementary analysis to other UroGen Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for UroGen Stock analysis
When running UroGen Pharma's price analysis, check to measure UroGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UroGen Pharma is operating at the current time. Most of UroGen Pharma's value examination focuses on studying past and present price action to predict the probability of UroGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UroGen Pharma's price. Additionally, you may evaluate how the addition of UroGen Pharma to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is UroGen Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.55) | Revenue Per Share 2.869 | Quarterly Revenue Growth 0.301 | Return On Assets (0.26) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.